Irmela Jeremias, MD, Helmholtz Munich, and LMU Munich, Munich, Germany, shares some insights into a study which used genetic barcoding to investigate the heterogeneity of acute myeloid leukemia (AML) cells and how this heterogeneity plays a role in resistance to therapy. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.